Hématologie
MENUIntensive chemotherapy in the elderly Volume 27, supplement 2, Mars 2021
Author
Université Cote d’Azur, Département d’hématologie, CHU de Nice, Nice, France
Inserm U1065, Centre méditerranéen de médecine moléculaire, Nice, France
Inserm U1065, Centre méditerranéen de médecine moléculaire, Nice, France
* Tirés à part
- Key words: Acute myeloid leukemia, intensive chemotherapy, targeted therapy
- DOI : 10.1684/hma.2021.1633
- Page(s) : 5-12
- Published in: 2021
Intensive chemotherapy is the standard treatment for acute myeloid leukemia. The selection of elderly patients who can benefit from this treatment has improved in recent years and the management of intensive chemotherapy has allowed more patients to access this treatment also allowing an increase in access to allogeneic cell transplantation. hematopoietic strains. Development is mainly carried out thanks to the French cooperative groups (ALFA and FILO) and thanks to academic studies making it possible to improve therapeutic strategies by integrating new therapies. This review provides an update on current standards and future prospects for intensive chemotherapy in acute myeloid leukemia.